Corvus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• Corvus Pharmaceuticals Inc CRVS.OQ reported a quarterly adjusted loss of 10 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -4 cents. The mean expectation of five analysts for the quarter was for a loss of 14 cents per share. Wall Street expected results to range from -16 cents to -12 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Corvus Pharmaceuticals Inc's reported EPS for the quarter was a loss of 10 cents​.

• The company reported a quarterly loss of $8 million.

• Corvus Pharmaceuticals Inc shares had risen by 4.2% this quarter and lost 22.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Corvus Pharmaceuticals Inc is $13.00, about 68.2% above its last closing price of $4.13

This summary was machine generated from LSEG data August 8 at 03:25 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)